The Bahrain Oncology Centre has successfully treated a sickle cell disease patient using CRISPR-based gene-editing therapy Casgevy, marking the first time the treatment has been administered outside the US. Casgevy is the first licensed therapy to utilize CRISPR/Cas9 gene-editing technology and is designed as a potential treatment for SCD and transfusion-dependent beta-thalassemia. Bahrain approved Casgevy for use, becoming the second country globally and the first in the Middle East to do so. The treatment involves collecting stem cells from the patient's bone marrow, genetically editing them, and reinfusing them after safety testing.